Test Directory

Test Code
6DMD
Test Name
Duchenne/Becker Muscular Dystrophy Carrier Screening
CPT Codes
81161
Expected Turnaround Time
Typically within 2 weeks from receipt of a sample in the laboratory
Clinical Utility
Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members.
Specimen and Container Info

Preferred/Alternate

Specimen Type

Containers

Volume

Preferred Specimen Type

Whole Blood

Lavender Top (EDTA)

3 mL

Alternate Specimen Type

Genomic DNA

1.5 mL Tube

3 µg (at a concentration of at least 30 ng/µl), preferably in TE solution.


NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico.

Transport Instructions
  • Transport at room temperature within 24 hours.
  • If the specimen cannot be transported to the lab within 24 hours, refrigerate for up to 72 hours.
  • Do not freeze or expose to extreme temperatures, refrigerate for up to 72 hours if cannot be transported to lab within 24 hours. 
Stability Requirements

Room Temperature

24 hours

Refrigerated

72 hours

Causes for Rejection
  • Improperly labeled specimen (minimum of two patient identifiers)
  • Inappropriate specimen type
  • Incomplete or incorrect test request form
  • Insufficient volume
  • Specimen has leaked in transit
  • Specimen without a test order
Methodology
Next Generation Sequencing and Copy Number Variation Analysis
Performing Location
Genomics - Snowdrift
Alternate Names
  • DMD
  • Becker muscular dystrophy
  • Cardiomyopathy, dilated, 3B
Description

This test is designed to detect carriers of Duchenne and Becker muscular dystrophy. Duchene muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked recessive disorders characterized by progressive muscle weakness and atrophy affecting skeletal muscles and the heart. DMD usually presents in males before the age of 5 and symptoms include difficulty running, climbing, and getting up from the floor. DMD progresses rapidly with wheelchair dependency by the age of 12 and death due to respiratory complications or dilated cardiomyopathy typically before the age of 30. BMD is a less severe disorder with later onset and slower progression. Males with BMD remain ambulatory beyond the age of 16 and typically live into their 40s with dilated cardiomyopathy the most common cause of death. Some males show little or no evidence of skeletal muscle disease but present with dilated cardiomyopathy, usually in their 20s to 40s. Targeted therapies may be available for some affected individuals and will likely improve the clinical course of these disorders. DMD (MIM 310200), BMD (MIM 300376), and DMD-associated dilated cardiomyopathy (MIM 302045) are caused by pathogenic variants in the DMD gene (NM_004006). The most common pathogenic variants in DMD are large deletions and duplications encompassing one or more exons of the gene. Females with a heterozygous pathogenic variant in DMD are carriers for a DMD-associated disorder. Male children of a female carrier have a 50% chance of being affected with the disorder. Female children of a female carrier have a 50% chance of being a carrier of the disorder. Additionally, females with a heterozygous pathogenic DMD variant may develop symptoms of these disorders, including muscle weakness and dilated cardiomyopathy. Pathogenic variants in DMD have a high incidence of de novo occurrence and germline mosaicism; therefore, individuals with a negative carrier screen may still be at risk for having a child with a DMD-associated disorder. This test is intended for pre/post-conception carrier screening and is not intended for diagnostic testing.

Testing Schedule
Monday-Friday
Genes
DMD
MIM
300376, 3020045, 310200